Business · 19/10/2026

Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS CRC, at ESMO 2026

PALO ALTO, Calif., Oct. 19, 2026 /PRNewswire/ -- Riboscience, a clinical-stage biotechnology company developing first-in-class immunotherapies, today announced that Phase 1b data for RBS2418, its lead oral ENPP1 inhib…